PLGA-PEG-COOH nanoparticles are efficient systems for delivery of mefloquine to Echinococcus multilocularis metacestodes.

Autier, Brice; Verger, Alexis; Plaisse, Charleen; Manuel, Christelle; Chollet-Krugler, Marylène; Preza, Matias; Lundström-Stadelmann, Britta; Amela-Cortes, Marian; Aninat, Caroline; Samson, Michel; Brandhonneur, Nolwenn; Dion, Sarah (2024). PLGA-PEG-COOH nanoparticles are efficient systems for delivery of mefloquine to Echinococcus multilocularis metacestodes. Experimental parasitology, 265, p. 108811. Elsevier 10.1016/j.exppara.2024.108811

[img]
Preview
Text
1-s2.0-S0014489424001140-main.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (5MB) | Preview

Alveolar echinococcosis (AE) is a severe disease caused by the infection with the larval stage of Echinococcus multilocularis, the metacestode. As there is no actual curative drug therapy, recommendations to manage AE patients are based on radical surgery and prophylactic administration of albendazole or mebendazole during 2 years to prevent relapses. There is an urgent need for new therapeutic strategies for the management of AE, as the drugs in use are only parasitostatic, and can induce toxicity. This study aimed at developing a drug delivery system for mefloquine, an antiparasitic compound which is highly active against E. multilocularis in vitro and in experimentally infected mice. We formulated mefloquine-loaded PLGA-PEG-COOH (poly-(lactic-co-glycolic acid)) nanoparticles that exhibit stable physical properties and mefloquine content. These nanoparticles crossed the outer acellular laminated layer of metacestodes in vitro and delivered their content to the inner germinal layer within less than 5 min. The in vitro anti-echinococcal activity of mefloquine was not altered during the formulation process. However, toxicity against hepatocytes was not reduced when compared to free mefloquine. Altogether, this study shows that mefloquine-loaded PLGA-PEG-COOH nanoparticles are promising candidates for drug delivery during AE treatment. However, strategies for direct parasite-specific targeting of these particles should be developed.

Item Type:

Journal Article (Original Article)

Division/Institute:

05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP) > Institute of Parasitology
05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP)

UniBE Contributor:

Preza Perez, Matias Facundo, Lundström Stadelmann, Britta

Subjects:

600 Technology > 630 Agriculture

ISSN:

0014-4894

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

08 Aug 2024 10:22

Last Modified:

12 Sep 2024 00:15

Publisher DOI:

10.1016/j.exppara.2024.108811

PubMed ID:

39111383

Uncontrolled Keywords:

EmPGI alveolar echinococcosis drug delivery system drug therapy poly(lactic co-glycolic acid)

BORIS DOI:

10.48350/199579

URI:

https://boris.unibe.ch/id/eprint/199579

Actions (login required)

Edit item Edit item
Provide Feedback